cyrilzakka/clinical-trials huggingface dataset:
ARTLifeLine: Assisted Reproduction Technology (ART) Family Health and Development Trajectory Cohort (ARTLL)

The goal of this observational study is to study the health status of infertile couples and their offspring using assisted reproductive technologies. The main questions it aims to answer are:

1. On the basis of the assisted reproduction birth cohort and related research established by the team in the early stage, further expand the construction of the "tracking cohort of familial health and development using assisted reproduction", combine emerging technologies such as cross-database linking and integration, multi-omics sequencing and classical cohort research design, and carry out long-term longitudinal follow-up across generations, covering the whole life cycle and health in multi-dimension.
2. Build a disease risk prediction model for pregnant women and children with assisted reproduction.
3. Delineate the growth curve and neurobehavioral development trajectory of assisted reproductive offspring at different stages.
4. Evaluate the adolescent fertility potential and risk factors of assisted reproductive offspring.

1. Recent Research Objectives (Within Five Years):

   Build a risk prediction model for reproductive women and children in assisted reproduction, and identify potential molecular markers with high predictive value to provide epidemiological evidence clues for further basic mechanism research.

   Analyze the health status of natural conception versus assisted reproduction pregnant women and children, growth and developmental curves of fetuses during pregnancy, and early neurobehavioral development levels of children after birth.
2. Medium to Long-Term Research Objectives (Future Research Directions of the Cohort):

Systematically evaluate the long-term effects of infertility and assisted reproductive treatments on the physiological, psychological, individual, and family development of parents and offspring.

Collaborate and share data with other domestic and international health cohorts or databases related to assisted reproduction, to compare and analyze the long-term safety of various assisted reproductive technologies on the health of infertile couples and their offspring.

Eligibility Criteria:
Inclusion Criteria:

(1) Previous or planned IVF treatment; (2) paper or electronic medical records during fertility treatment are available; (3) Obtain informed consent from the research subject or guardian of the minor.

Exclusion Criteria:

(1) Other assisted reproductive treatment techniques that exclude in vitro fertilization, including guided intercourse, ovulation induction, artificial insemination, etc.; (2) refusal of enrollment; (3) withdraw or abort the study at any time and for any reason.
Cough Sound Recordings to Understand COVID-19-like Symptom Progression to Understand COVID-19-like Symptom Progression

Decentralized clinical study designed to collect further cough sounds, self-reported symptoms, and medical treatment questionnaires from participants enrolled on the COVID-Cough Study ("Study 1").

The aim of this further data collection study ("Study 2") is to:

1. develop an understanding of changes in cough sounds associated with COVID-19 and how they alter during the disease;
2. develop an understanding of other causes of COVID-19-like symptoms and their associated cough sound patterns; and
3. gain a broader understanding of the clinical outcomes of individuals who present for COVID-19 testing.

This study is designed to be administered in a decentralized manner to collect self-reported COVID-19 symptoms, cough sample recordings and descriptions of recent medical treatment to investigate the following:

1. Whether patterns unique to COVID-19 disease can be detected in cough sounds collected over time;
2. The incidence of COVID-19 and other lung diseases within individuals who test negative for COVID-19;
3. Whether existing machine learning algorithms can detect the presence of disease in the lower respiratory tract in participants; and
4. Whether distinct cough sound patterns in COVID-19 disease are associated with the requirement of medical treatment for COVID-19 disease. Through the administration of Study 1, a list of potential participants will be created for whom the result of a recent rt-qPCR COVID-19 test is known. Participants have been consented to allow for outreach regarding further studies. Cough samples and answers to medical questions have been collected from these individuals at the time of testing, and the aim of Study 2 is to gather further cough samples and questionnaire answers over a period of 25 days.

Eligibility Criteria:
Inclusion Criteria:

* be aged 21 years and older;
* be a resident of the USA;
* have a personal (i.e., not shared) iPhone 6s or newer running iOS 14 or later;
* be able to read and understand English;
* be able to provide informed consent;
* be willing to follow study procedures;
* be able to provide at least 5 coughs (voluntary and/or spontaneous);
* have enrolled in the COVID-Cough Study and successfully returned an at-home rt-qPCR test to the study partner laboratory

Exclusion Criteria:

Participant has one or more medical contraindication to voluntary cough, including the following:

* Severe respiratory distress;
* History of pneumothorax;
* Eye, chest, or abdominal surgery within 3 months of enrolling for the study; or
* Hemoptysis (coughing up of blood) within 1 month of enrolling for the study;
Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)

In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

We conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory CP-CPPS (National Institutes of Health (NIH) type IIIA). Participants were randomized to Cernilton or placebo for 12 weeks and were evaluated using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) individual domains and total score, the number of leukocytes in post prostatic massage urine, the International Prostate Symptom Score (IPSS) and the sexuality domain of a life satisfaction questionnaire at baseline and after 6 and 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* men between 18 and 65 years
* symptoms of pelvic pain for at least 3 months during the 6 months before study entry
* a score in the pain domain of the German validated version of the NIH chronic prostatitis symptom index (NIH-CPSI) of 7 or higher
* leukocytes of 10 or more in post prostate massage urine

Exclusion Criteria:

* urinary tract infection
* acute bacterial or chronic bacterial prostatitis
* history of urethritis with discharge 4 weeks prior to study entry
* a history of epididymitis or sexually transmitted disease
* residual urine volume of more than 50 mL due to bladder outlet obstruction
* indication for or history of prostate surgery including prostate biopsy
* treatment with phytotherapeutic agents
* alpha-blocker agents or antimicrobial substances with prostatic penetration 4 weeks prior to study entry
* treatment with agents influencing intraprostatic hormone metabolism 6 months prior to study entry
Phase Angle and Chronic Intestinal Inflammatory Diseases

Phase angle (PhA) is a biometric parameter measured by bioimpedance analysis (BIA), which reflects organism cellularity and tissues hydration. In addition, since it correlates with the presence of inflammation and the nutritional status, it could be useful to monitor inflammatory bowel disease (IBD) activity. The aim of this study was to establish the potential use of PhA as a new non-invasive and sensitive marker correlated with mucosal healing and/or IBD activity.

Currently, fecal calprotectin is considered the best indirect marker inversely correlated with the mucosal healing in patients with inflammatory bowel disease (IBD). C reactive protein (CRP), is less reliable than fecal calprotectin in the evaluation of IBD activity. In order to establish the potential use of phase angle (PhA) as a new non-invasive and sensitive marker of mucosal healing and/or disease activity in patients with IBD, patients with diagnosis of chronic inflammatory bowel diseases (IBD) according to the European Crohn's and Colitis Organization (ECCO) guidelines will be enrolled. In these patients, the following parameters will be evaluated: age, sex, body mass index (BMI), percentage of weight loss in the last 6 months, duration of illness, location of disease, any previous intestinal surgery, ongoing therapy for IBD, activity disease by clinical scores, CRP, fecal calprotectin, disease activity by endoscopic scores, PhA and fat free mass (FFM).

Eligibility Criteria:
Inclusion Criteria:

* histological report confirming the diagnosis of IBD,
* value of C-reactive protein (CRP)
* fecal calprotectin,
* colonoscopy within 3 months from the enrollment.

Exclusion Criteria:

* presence of ascites or edema,
* chronic or autoimmune inflammatory diseases,
* ongoing infections,
* recent surgery (in the last 6 months),
* neoplastic diseases,
* ongoing enteral or parenteral nutrition,
* presence of fistulae,
* ileostomy or colostomy,
* short bowel syndrome,
* pregnancy or lactation.
Efficacy of Patient Controlled Epidural Anesthesia Versus Continuous Epidural Analgesia for Post-thoracotomy Pain

Postoperative thoracotomy pain is normally managed with an epidural catheter and continuous epidural analgesia (CEA). However, for some surgical procedures, patient controlled epidural anesthesia (PCEA) is more effective but little research has compared the two methods following thoracotomy. The current randomized, prospective clinical investigation did just this. Following institutional ethics approval 52 patients scheduled for thoracotomy were recruited for this prospective, randomized, unblinded study. A thoracic epidural catheter was sited preoperatively. Postoperatively all patients were titrated on continuous epidural infusions (hydromorphone 10 mcg/mL + bupivacaine 1 mg/mL) until pain scores were stable at ≤3 on a numeric rating scale (NRS). Then they were allocated to their preoperatively determined randomization (either remained on continuous epidural infusion or they were switched to receive 2/3 of the stabilized background dose via continuous epidural infusion with the option to self-administer the remaining 1/3rd of the dose via PCEA. Participants remained on their allocated analgesic regimens for 48 hours postoperatively. The primary outcome was consumption of local anaesthetics/opioids. The secondary outcomes were worst pain and pain while coughing (0-10 NRS).


Eligibility Criteria:
Inclusion Criteria:

* 18-75 years of age
* American Society of Anesthesiologist's (ASA) Physical Status I-III
* Body Mass Index (BMI) \< 40
* Able to use a PCEA device

Exclusion Criteria:

* Intolerance/hypersensitivity to agents used in the study
* Contraindication to epidural placement
* Current alcohol/substance abuse
* Chronic pain condition requiring chronic analgesic
* BMI ≥ 40 or body weight less than 50kg.
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of Japanese men and women. The investigators will also investigate novel risk factors for metabolic and cardiovascular disease using molecular weight-based metallomics analysis.

Obesity is on the rise worldwide and is the most important risk factor for lifestyle-related diseases, including type 2 diabetes, hypertension, dyslipidemia, metabolic syndrome, ischemic heart disease, cerebrovascular disease, hyperuricemia, and chronic kidney disease. In addition, it has been reported that the distribution of fat is more important than the total amount of fat in the body, and the importance of visceral fat accumulation in the abdomen has been reported.

Although visceral fat accumulation and insulin resistance have been reported to be important upstream factors in the development of lifestyle-related diseases, the major target organs of insulin are not only adipose tissue, but also extremely important tissues such as muscle and liver, and ectopic fat accumulation in these tissues has attracted attention. However, there are few prospective cohort studies that have evaluated fat accumulation in adipose tissue, liver, and muscle simultaneously.

It has been reported that Japanese people have more visceral fat than Caucasians in the United States, even at the same body mass index level, and are at high risk for type 2 diabetes, so research on Japanese people is of great importance.

In addition, the role of trace elements in the body is attracting attention. In this cohort study, the investigators will also examine the relationship between trace elements in the body and the prevalence and incidence of lifestyle-related diseases.

The purpose of this study is to establish a prospective cohort study that evaluates visceral fat, subcutaneous fat, intrahepatic fat accumulation, and intramuscular fat using computed tomography imaging and to clarify the relationship with lifestyle-related diseases such as type 2 diabetes, hypertension, dyslipidemia, metabolic syndrome, ischemic heart disease, cerebrovascular disease, hyperuricemia, and chronic kidney disease.

Eligibility Criteria:
Inclusion Criteria:

-

Exclusion Criteria:

* Women who may be pregnant
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

The main objective of this study is to assess whether a recently-developed bioassay for the protein FGL2 can be used to predict the progression and/or response to treatment of Hepatitis C Virus disease in patients with chronic HCV infection. The hypothesis is that increased levels of FGL2 and increased numbers of T regulatory cells are associated with a failure to respond to treatment.

The current therapy for chronic Hepatitis C Virus infection leads to a sustained viral response in only 50% of treated patients. Evidence suggests that a poor response to treatment may be the result of a dysfunction of immunoregulatory mediators including T regulatory cells (Tregs) which secrete FGL2. The aim of this study is to test whether serum FGL2 levels can serve as a biomarker for clinical progress and treatment response in patients undergoing anti-viral therapy for chronic HCV infection.

This study will measure the blood Treg and FGL2 levels of patients with chronic Hepatitis C as they undergo antiviral therapy and will compare those levels to their pre-treatment and post-treatment levels. Treg and FGL2 expression levels will also be measured in patients' liver biopsy tissue when available.

Additionally, this study will examine the main form(s)of Fc Receptor expressed in these patients. The Fc receptor is the hypothesized binding partner of FGL2, and the form expressed in a given patient may determine the downstream effects of FGL2's binding. These data along with clinical, biochemical and virological data will be used to determine whether there is a correlation between FGL2 levels and disease outcome and/or treatment response.

The study will also recruit a group of normal healthy volunteers to give blood samples on two occasions so that the baseline range of FGL2 levels in healthy individuals can be established for comparison.

Eligibility Criteria:
HCV patient population

Inclusion Criteria:

* able to give written consent
* 18-70 yrs of age, both genders
* willing to use adequate contraception
* diagnosis of chronic HCV infection (of any genotype) based on 2 positive serology tests
* availability of pre- and post-treatment viral load data
* naive to antiviral treatment
* availability of pre-treatment liver biopsy

Exclusion Criteria:

* less than 18 yrs, greater than 70 yrs of age
* pregnancy
* HBV, HDV, or HIV co-infection
* any history of active alcohol or drug abuse

Volunteer Population (Control)

Inclusion Criteria:

* able and willing to provide written informed consent
* willing to provide a brief review of medical history
* 18-70 yrs of age, of either gender

Exclusion Criteria:

* less than 18, greater than 70 yrs of age
* any history of liver, renal, lung, hematological or coronary artery disease
* any history of active alcohol or drug abuse
* any previous diagnosis of HBV, HCV, HDV or HIV
A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms

This twelve-week trial will examine the effectiveness of a Menning Labs EQ Product Line acne product. Participants will use the exfoliating cleanser, cream, and gel daily for 8 weeks. Participants will complete questionnaires at Baseline, Day 1, Day 3, Day 7, Day 28, Day 42, and Day 56. Participants will also provide before-and-after photos at Baseline, Day 7, and Day 42, as well as undergo expert skin grading at Baseline and Day 42. The questionnaire on Day 56 will mark the conclusion of the trial.


Eligibility Criteria:
Inclusion Criteria:

* Be aged between 18-45.
* Anyone who has acne prone skin and a history of recurring acne.
* Has visible acne at enrollment.
* Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
* Have a digital camera or smartphone to take photos of the face.

Exclusion Criteria:

* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
* Anyone currently using a prescription skin product.
* Anyone who is unwilling to stop using the current acne supplements they are taking.
* Anyone with known severe allergic reactions.
* Any women who are pregnant, breastfeeding or attempting to become pregnant.
* Anyone unwilling to follow the study protocol.
* Anyone who identifies as having sensitive skin.
Effect of COVID-19 Infection on Obstertric Complications and Maternal Outcomes

This study aimed to evaluate the effect of COVID-19 infection on obstetric complications and maternal outcomes.

During the SARS-CoV-2 pandemic, pregnant women were reported to have a higher susceptibility to COVID-19 infection. Pregnant women who tested positive for SARS-CoV-2 are at higher risk of a severe form of COVID-19, associated with higher rates of intensive care unit (ICU) admission and increased needs for respiratory support, compared to the age-matched non-pregnant population.

Women infected during pregnancy also have an increased risk of adverse pregnancy outcomes including preterm-birth, with a significant proportion secondary to iatrogenic preterm birth due to maternal illness. Infection with SARS-CoV-2 during pregnancy has also been reported to be associated with a higher risk of stillbirth directly or indirectly caused by the virus.

Infected pregnant patients tended to present asymptomatically with pre-Delta and Omicron variants, and symptomatically with Delta variant. A previous systematic review suggested that people who are pregnant did not have an increased risk of SARS-CoV-2 infection or symptomatic COVID-19, but they were at risk of severe COVID-19 compared with those who were not pregnant.

Eligibility Criteria:
Inclusion Criteria:

* Age from 18 to 40 years.
* Pregnant women with COVID-19 infection diagnosed either by PCR or rapid test.

Exclusion Criteria:

• Patients vaccinated for COVID-19 before or during the current pregnancy.
Envarsus XR in African American Renal Transplant Recipients

The purpose of this study is to collect data prospectively on African American patients who are taking the immunosuppressant Envarsus post kidney transplant. We are looking to see if African American renal transplant recipients that receive Envarsus will have less tubular injury and calcenurin inhibitor toxicity compared with patients that receive tacrolimus IR.

African americans have the higher rates of CYP3A5 which is associated with the need of higher tacrolimus dose to achieve an adequate level and this many times is associated with signs and symptoms of tacrolimus toxicity such as tremors, headaches and neuropathies.

The retrospective cohort will be African American patients that will be matched by age, gender, type of kidney transplant (living vs deceased) and level of sensitization


Eligibility Criteria:
Inclusion Criteria:

1. African American race
2. Adult renal transplant recipients (\>18 y/o)
3. Previous adverse reaction or contraindication to the use of tacrolimus

Exclusion Criteria:

1. Non African American race
2. Less than 18 y/o (pediatric patients)
3. Recipients of liver and small bowel transplants
4. Adverse reaction to tacrolimus
Study on the Oxygen Saturation in Pulsating and Non-pulsating Central Retinal Veins

Retinal ischemia is thought to play an important role in the pathogenesis of glaucoma. Recent findings have confirmed that there is a direct correlation between the levels of venous oxygen saturation and the degree of the glaucomatous disease, presumably due to a decrease in retinal cell metabolism.

However, glaucoma patients have been suggested to have a different pattern in retinal venous circulation. For instance, the observation of a visible pulsating central retinal vein is a phenomenon that can be seen in up to 98% of the healthy individuals but is identifiable in less than 50% of glaucoma patients. While the nature of these venous changes are not year clear, the lack of a visible pulsating flow could suggest an increased intraluminal venous pressure due to some obstruction from both ocular or extraocular structures. This undetermined increase in venous pulse pressure could then significantly decrease perfusion pressures and therefore further decrease oxygen supply to the retinal tissues.

The investigators will therefore try to determine if there is a significant difference between the oxygen saturation of the retinal vessels in both glaucoma patients with and without a visible pulsating central vein

1. Visual field examen will be performed.
2. Structural examination of the optic disc (confocal microscopy) will be performed.
3. Spontaneous venous pulsation will be recorded after a one minute fundoscopy observation.
4. Oximetry reading in the non-contact retinal oximetry of the first 3 order retinal vessels

Eligibility Criteria:
Inclusion Criteria:

* individuals over 18 years old
* willing to sign an informed consent and able to comply with the requirements of the study
* having no other ocular diseases besides glaucoma

Exclusion Criteria:

* history of ocular trauma
* intraocular surgery (except for cataract surgery)
* eye disease (except glaucoma)
* systemic diseases with ocular involvement like diabetes